What is PCOS?

Polycystic Ovary Syndrome (PCOS) is one of the most common hormonal conditions in women of reproductive age, affecting an estimated 1 in 10 women globally — and many of whom remain undiagnosed for years. Despite its name, ovarian cysts are not the defining feature of the condition, nor are they present in all cases. PCOS is more accurately understood as a syndrome of hormonal and metabolic dysregulation characterised by a cluster of overlapping features.

The Insulin Connection: Why PCOS Is a Metabolic Condition

Insulin resistance is present in 70–80% of women with PCOS — including lean women with no apparent weight issue. This makes it the most consistent metabolic feature of the condition, and the strongest argument for understanding PCOS as fundamentally a metabolic disorder that expresses itself hormonally, rather than a hormonal disorder with incidental metabolic consequences.

How Insulin Resistance Drives Hormone Dysregulation

The ovaries contain insulin receptors, and insulin normally plays a supportive role in reproductive function. But when insulin levels are chronically elevated — as they are in insulin resistance — the ovaries receive a sustained signal to produce more androgens (predominantly testosterone). At the same time, elevated insulin suppresses sex hormone-binding globulin (SHBG) production in the liver, which means more testosterone circulates in its biologically active, unbound form. The result is the androgen excess that drives the most visible symptoms of PCOS: acne, hirsutism, and irregular cycles.

The LH-to-FSH ratio — a key hormonal marker in PCOS — is also disrupted by chronic insulin elevation, which amplifies the pituitary's LH output while leaving FSH relatively suppressed. This imbalance impairs follicular development and ovulation, contributing to cycle irregularity and the reproductive health challenges many women with PCOS experience.

Why Lean Women Get PCOS Too

The persistent association of PCOS with weight gain has led to a widespread and damaging misconception: that PCOS is a condition of overweight women, and that weight loss will resolve it. Research
exploring why women and men metabolise fructose differently — and what this means for women's hormonal health reveals a more nuanced picture. Insulin resistance in PCOS is not always weight-dependent; it can be driven by the same fructokinase-mediated metabolic disruption in lean women, with different body composition consequences but identical hormonal sequelae.

Reference: Dunaif, A. (1997). Insulin resistance and the polycystic ovary syndrome. Endocrine Reviews.

Fructose and PCOS: The Fructokinase Cascade

If insulin resistance is the mechanism through which PCOS symptoms are generated, fructose metabolism — and specifically, the unregulated activity of the enzyme fructokinase — is increasingly being examined as a primary driver of that insulin resistance in the context of modern diets.

Androgen Excess: Acne, Hair, and the Insulin Signal 

For many women, androgen excess is the most distressing and visible dimension of PCOS. Acne that persists beyond adolescence, unwanted facial or body hair, and scalp hair thinning are not cosmetic inconveniences — they are markers of a deeper hormonal imbalance that reflects the degree of insulin dysregulation at the ovarian level.

The mechanism is precise: elevated insulin acts directly on ovarian theca cells, upregulating the enzymes responsible for testosterone synthesis. At the same time, elevated insulin suppresses liver production of SHBG — the protein that binds testosterone and renders it biologically inactive. The result is a double amplification: more testosterone produced, less testosterone bound, meaning more active androgen driving the symptoms of hirsutism, acne, and alopecia.

Sebaceous (oil-producing) glands in skin are directly stimulated by DHT (dihydrotestosterone, the more potent form of testosterone converted from free testosterone by 5α-reductase). Elevated DHT increases sebum production, enlarges pores, and creates the conditions for comedones, cysts, and inflammatory acne — a cycle that continues as long as insulin resistance and androgen excess persist.

Why Diet Alone Often Fails: Endogenous Fructose and PCOS

One of the most clinically significant — and least discussed — aspects of PCOS management is the endogenous fructose problem. Many women with PCOS who have diligently eliminated added sugars, reduced refined carbohydrates, and adopted low-GI eating patterns continue to experience insulin resistance, persistent symptoms, and frustrating metabolic stagnation. The polyol pathway is a key reason why.

Under physiological stress — including high blood glucose, chronic dehydration, elevated cortisol, and high-salt dietary patterns — the body converts glucose to fructose internally via the polyol pathway (glucose → sorbitol → fructose). This internally generated fructose activates fructokinase in exactly the same way as dietary fructose, contributing to ATP depletion, uric acid accumulation, and the ongoing insulin resistance that drives PCOS symptoms — entirely independent of what a woman is eating.

Cortisol: The Stress Amplifier That Worsens PCOS

Cortisol is the body's primary stress hormone — an essential short-term regulator that becomes problematic when chronically elevated. For women with PCOS, the cortisol connection is particularly consequential because cortisol and insulin interact in ways that compound each other's hormonal effects. Elevated cortisol raises blood glucose (triggering more insulin), promotes abdominal fat storage, suppresses sex hormone production, and impairs the hypothalamic-pituitary-ovarian (HPO) axis — the very signalling network that regulates the menstrual cycle.

The timing of cortisol elevation matters too. Morning cortisol follows a natural peak (the cortisol awakening response, or CAR) that primes the metabolic system for the day. When this morning cortisol spike combines with a high fructose or high-carbohydrate breakfast, the resulting insulin surge is disproportionately large — creating hormonal conditions in the early hours that can set the tone for blood sugar and energy instability throughout the day. Research examining how morning cortisol and breakfast sugar intake compound to drive metabolic fatigue and hormonal disruption makes a compelling case for reconsidering what the first meal of the day contains — particularly for women with PCOS.

Reference: Pasquali, R., et al. (1993). Effects of acute hyperinsulinaemia on testosterone serum concentrations in adult obese and normal-weight men. Metabolism.

Adrenal Fatigue and PCOS: The Cortisol–Insulin Feedback Loop

A subset of women with PCOS have what is sometimes described as "adrenal PCOS" — a presentation in which elevated androgens derive primarily from the adrenal glands (DHEA-S) rather than from the ovaries. In these cases, chronic HPA axis dysregulation — the pattern often associated with the lay term "adrenal fatigue" — is the primary driver, with cortisol excess stimulating adrenal androgen production rather than ovarian testosterone overproduction.

Whether PCOS is ovarian or adrenal in origin, the underlying metabolic environment — chronic insulin resistance, mitochondrial stress, and elevated fructokinase activity — creates the same downstream hormonal disruption. And the symptom experience is often nearly identical: fatigue that is disproportionate to activity level, persistent sugar cravings (particularly in the afternoon), mood instability, and difficulty recovering from physical or emotional demands.

Understanding the symptoms associated with adrenal and cortisol dysregulation — and how
they overlap with PCOS — and what metabolic strategies may help is an important part of the clinical picture for women who do not fit the classic ovarian PCOS profile but recognise the hormonal and metabolic symptom pattern.

Perimenopause and PCOS: When Metabolic Transitions Collide

PCOS does not simply resolve at menopause. Women with PCOS who enter the perimenopause transition — typically beginning in the mid-40s — often find that symptoms which had been partially managed become more pronounced as ovarian function declines and the metabolic landscape shifts. Oestrogen's protective role in insulin sensitivity, body composition, and vascular health diminishes during perimenopause, removing a metabolic buffer that many women with PCOS had been unknowingly relying on.

The perimenopause transition typically involves greater variability in cycle length and hormonal fluctuation — but for women with PCOS, this variability is superimposed on an already dysregulated hormonal system. The result can be an intensification of metabolic symptoms: worsened insulin resistance, accelerated visceral fat
accumulation, more severe fatigue, and new or worsened mood disruptions, particularly in relation to blood sugar instability.

Research exploring how fructose metabolism interacts with the perimenopausal hormonal shift to amplify metabolic symptoms provides important context for women who are navigating both conditions simultaneously — and for clinicians who may not fully appreciate the compounding nature of this overlap.

Luteolin and Female Hormones: What the Research Shows

For women considering a natural supplement approach to supporting hormonal balance, the question of how a compound interacts with female reproductive hormones is an important and reasonable one. Luteolin — the primary active compound in SugarShield — has been studied specifically in the context of oestrogen and progesterone biology, with research examining whether it modulates, mimics, or otherwise interacts with female sex hormone pathways.

The available evidence, summarised in a detailed research review of whether luteolin affects oestrogen and progesterone levels and signalling, is reassuring in its nuance: luteolin's biological activity in this area is not that of a phyto-oestrogen (weak oestrogen mimic) but rather a modulator of inflammatory and metabolic signalling pathways that sit upstream of hormone production. Its primary relevance in the context of PCOS is through its action on fructokinase, insulin signalling, and the downstream mitochondrial and inflammatory pathways — not through direct hormonal intervention.

This distinction is important for women with PCOS who may have been advised to be cautious with phyto-oestrogenic compounds. Luteolin's mechanism of action in metabolic health support — upstream at the enzyme level — does not carry the same considerations as compounds that directly modulate oestrogen receptor activity.

📖 RESEARCH NOTE

The research on luteolin and female hormones cited above is based on preclinical and mechanistic data. Clinical evidence in women with PCOS specifically is still limited. Women who are pregnant, trying to conceive, or managing oestrogen-sensitive conditions should consult their healthcare provider before beginning any new supplement.

Restoring Metabolic Balance: What Addressing the Root Cause May Mean

PCOS symptoms do not require a purely symptomatic solution. Because insulin resistance is the central defect, and because fructokinase-driven metabolic disruption is a key driver of that insulin resistance, addressing the upstream enzymatic source of the problem creates the conditions for multiple downstream improvements — simultaneously, and through a single mechanism rather than five separate interventions.

When insulin sensitivity improves and mitochondrial stress reduces, the hormonal environment that drives PCOS shifts in ways that many women notice clinically:

• More regular menstrual cycles — as LH/FSH signalling normalises and follicular development resumes a more consistent rhythm
• Reduced androgen-driven symptoms — acne, hirsutism, and scalp thinning may ease as testosterone production decreases and SHBG levels rise
• Reduced cravings and improved appetite regulation — as leptin signalling and dopamine sensitivity are restored through improved insulin dynamics
• Improved energy and mood stability — as mitochondrial ATP production normalises and the cortisol-insulin feedback loop is attenuated
• More manageable weight — not through caloric restriction, but through restoration of the metabolic signalling conditions under which the body can access and burn stored fat

At LIV3, our position is that PCOS is a metabolic condition at its core. Targeting fructose metabolism — specifically the fructokinase step — is one of the most direct upstream interventions available, because it addresses the enzymatic process that initiates the insulin resistance, mitochondrial stress, and inflammation from which PCOS symptoms cascade.

SugarShield delivers liposomal luteolin — the compound studied for its capacity to modulate fructokinase activity — alongside tart cherry extract, in a formulation designed to support healthy fructose metabolism and the downstream hormonal and metabolic balance that depends on it.

These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. SugarShield is a dietary supplement. It is not a treatment for PCOS or any hormonal condition. Women with PCOS should work with a qualified healthcare provider to manage their condition.

Insulin resistance is both cause and consequence of PCOS — learn how reversing insulin resistance addresses a root cause of PCOS symptoms to tackle both conditions simultaneously.

Continue Exploring the PCOS and Women's Metabolic Health Series

• The Complete Fructose Metabolism Guide — foundational science from enzyme to hormonal consequences
•  PCOS: Clinical Reference and Research Overview — diagnostic criteria, presentations, and the metabolic model
• Sugar's Hidden Impact on Women's Hormones — how dietary fructose uniquely affects female endocrine function
• The Fructose Paradox: Gender Differences in Metabolic Response — why women's fructose metabolism differs from men's 
• Fructose and the Perimenopause Transition — how metabolic change amplifies hormonal disruption
• Luteolin and Female Sex Hormones: What the Research Shows — evidence review of luteolin's interaction with oestrogen and progesterone
• Adrenal Fatigue Symptoms and PCOS — the cortisol-insulin loop and how to recognise adrenal-driven hormonal patterns